Experience the benefits of 2 to 3 fewer shots in the infant vaccination series compared to pentavalent vaccines (+ hep B or Hib vaccine)1,2,3,4

VAXELIS may reduce the number of shots that infants and parents must endure in the first 6 months—with as few as 2 injections per visit1,2,3,4

VAXELIS™ May Reduce the Number of Shots That Infants and Parents Must Endure in the First 6 Months With as Few as 2 Injections Per Visit
Table Shows Dosing Schedule for VAXELIS™

aOral rotavirus vaccine may be administered as a 2-dose series (at 2 and 4 months) or a 3-dose series (at 2, 4, and 6 months), depending on brand.4

Learn more about the VAXELIS and pentavalent vaccination schedules by viewing the Transition Tool.


The CDC, AAP, and AAFP guidelines include the use of a 4-dose hepatitis B vaccine schedule4,5

To help protect patients at birth, the guidelines support routinely giving the monovalent hepatitis B vaccine birth dose followed by a combination vaccine at 2, 4, and 6 months5

  • Recommended minimum intervals between doses should be maintained, and the last dose of hepatitis B vaccine should be given at ≥24 weeks4,5

AAFP, American Academy of Family Physicians; AAP, American Academy of Pediatrics; CDC, Centers for Disease Control and Prevention.

Important Safety Information
  • Do not administer VAXELIS to anyone with a history of severe allergic reaction to a previous dose of VAXELIS, any ingredient of VAXELIS, or any other diphtheria toxoid, tetanus toxoid, pertussis-containing vaccine, inactivated poliovirus vaccine, hepatitis B vaccine, or Hib vaccine.
  • Do not administer VAXELIS to anyone with a history of encephalopathy within 7 days of a pertussis-containing vaccine with no other identifiable cause.
  • Do not administer VAXELIS to anyone with a history of progressive neurologic disorder until a treatment regimen has been established and the condition has stabilized.
  • Carefully consider benefits and risks before administering VAXELIS to persons with a history of: fever ≥40.5°C (≥105°F), hypotonic-hyporesponsive episode (HHE), or persistent, inconsolable crying lasting ≥3 hours within 48 hours after a previous pertussis-containing vaccine; and/or seizures within 3 days after a previous pertussis-containing vaccine.
  • If Guillain-Barré syndrome occurred within 6 weeks of receipt of a prior vaccine containing tetanus toxoid, the risk for Guillain-Barré syndrome may be increased following VAXELIS.
  • Apnea following intramuscular vaccination has been observed in some infants born prematurely. Consider the individual infant’s medical status and potential benefits and possible risks of intramuscular vaccination in deciding when to administer VAXELIS to an infant born prematurely.
  • Vaccination with VAXELIS may not protect all individuals.
  • The solicited adverse reactions 0-5 days following any dose were irritability (≥55%), crying (≥45%), injection site pain (≥44%), somnolence (≥40%), injection site erythema (≥25%), decreased appetite (≥23%), fever ≥38.0°C (≥19%), injection site swelling (≥18%), and vomiting (≥9%).
  • The 3-dose immunization series consists of a 0.5 mL intramuscular injection, administered at 2, 4, and 6 months of age.
  • A 3-dose series of VAXELIS does not constitute a primary immunization series against pertussis; an additional dose of pertussis-containing vaccine is needed to complete the primary series.

Before administering VAXELIS, please read the Prescribing Information. The Patient Information also is available.